BCG: a therapeutic modality for COVID-19 and cancers
The Bioidea group invites you to join healthcare, biotech and investment community for the virtual session featuring distinguished clinicians and scientists working on the BCG vaccine for COVID-19 and cancer. Our webinar will also discuss how BCG modality can be exploited to construct next-generation genetically-engineered therapies. Event is to be live streamed to multiple platforms.
Bacillus Calmette–Guérin (BCG) is a live attenuated vaccine that was developed against tuberculosis at the beginning of the 20th century. BCG is also approved as a treatment for early-stage baldder cancer. The recent studies revealed a correlation showing that countries with higher rates of BCG vaccinations had lower peak mortality rates from COVID-19. Receiving BCG vaccination during early childhood is associated with reduced risk of subsequent lung cancer development. These beneficial effect of BCG against viral infections are proposed to be mediated by the stimulation of innate immune mechanisms, also termed trained immunity
WHEN: Wednesday July 22, 4:15 – 5:00 PM ET
WHERE: ZOOM (link to be send to registered / vetted participants)
RSVP to register and receive Zoom link: https://bcg-vaccine-advances.eventbrite.com
Panelists
Dr. Leonardo O. Reis, MD PhD. Professor Livre Docente Urologia Produtividade Pesquisa CNPq, UroScience / Urology / Oncology Dr Seth Lerner, MD. Professor of Urology. Beth and Dave Swalm Chair in Urologic Oncology Director of Urologic Oncology, Director of the Multidisciplinary Bladder Cancer Program Urology, Baylor College of Medicine, Houston, TX, US Dr Andrew DiNardo, MD. Assistant Professor. Medicine-Infectious Disease, Baylor College of Medicine Houston, TX, US Dr Ashish Kamat, MD. Professor of Urologic Oncology. Wayne B. Duddlesten Professor of Cancer Research, Attending Surgeon, Department of Urology, Division of Surgery, The University of Texas, MD Anderson Cancer Center Dr Jessica Seeliger, PhD. Associate Professor, Department of Pharmacological Sciences, Stony Brook University. Microbial Pathogenesis. Dr Yossef Av-Gay, PhD. Professor, Division Of Infectious Diseases, The University Of British Columbia Dr Lewis Schrager, MD. Infectious Diseases, TB. Former VP, Scientific Affairs at Aeras Dr Naomi E. Aronson, MD. Professor of Medicine , Director, Infectious Diseases Division , Uniformed Services University of the Health Sciences Dr Jordi Orchando, PhD. Assistant Professor, Oncological Sciences, The Icahn School of Medicine at Mount Sinai Dr Boris Shor, PhD. Manhattan BioSolutions, Inc. Founder & CEO The views expressed by Dr. Aronson are those of the presenter and do not reflect the official policy or position of her institution (the Uniformed Services University), the Department of Defense or the US government
Event Moderators Dr Navpaul Singh, MD. Chief Medical Consultant, Nascent Biotechnology
Selected Clinical Trails Assessing BCG For COVID-19
- BCG Vaccine for Health Care Workers as Defense Against COVID 19 (BADAS) NCT04348370,United States - COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement (BATTLE) NCT04369794, Brazil - Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity (COBRA) NCT04439045, Canada - Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic NCT04373291, Denmark - BCG Vaccination for Healthcare Workers in COVID-19 Pandemic NCT04379336, South Africa - BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE) NCT04327206, Australia - Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers (COVID-BCG) NCT04384549, France - Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA) NCT04328441, Netherlands - Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic NCT04387409, Germany - Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic NCT04435379, Germany
